NCT00203099View on ClinicalTrials.gov

Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

June 30, 2008

Conditions
Relapse Remitting Multiple Sclerosis
Interventions
DRUG

Glatiramer Acetate, N-Acetylcysteine

Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00203099 - Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine | Biotech Hunter | Biotech Hunter